For taselisib, studies have shown that in patients with HER2‐negative, hormone receptor‐positive advanced breast cancer, regardless of PIK3CA mutation status, the combination of taselisib and fulvestrant has clinical activity.68, 69. This evidence concerns the gene PIK3CA and breast carcinoma.